SCHEMBL17755626

SCHEMBL17755626

CN1/C(=N/Cc2cccc(Cl)c2)C2(CCCCC2)N(C)c2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACAT2 Q9BWD1 1/20 0.38
▸ AMPD2 Q01433 1/20 0.36
▸ SIGMAR1 Q99720 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KCNQ2 O43526 2/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ SLC6A4 P31645 3/20 0.34
▸ SLC6A3 Q01959 3/20 0.34
▸ SLC6A2 P23975 2/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ TSHR P16473 2/20 0.34
▸ FSHR P23945 2/20 0.34
▸ HTR3E A5X5Y0 1/20 0.33
▸ HTR3B O95264 1/20 0.33
▸ HTR3A P46098 1/20 0.33
▸ HTR3D Q70Z44 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17757990 0.80 ACAT2 (0.51) ACAT2AMPD2SIGMAR1CYP2C9CYP2C19
SCHEMBL17757272 0.79 ACAT2 (0.50) ACAT2AMPD2SIGMAR1CYP2C9CYP2C19
SCHEMBL17757265 0.69 P2RX7 (0.38) CYP2C9CYP2C19CYP1A2GAASMN1; SMN2
SCHEMBL17757949 0.66 ACAT2 (0.43) ACAT2AMPD2SIGMAR1CYP2C9CYP2C19
SCHEMBL17757951 0.66 ACAT2 (0.56) ACAT2CYP2C9CYP2C19GAASLC6A4
SCHEMBL17757268 0.64 ACAT2 (0.46) ACAT2AMPD2SIGMAR1SMN1; SMN2TDP1
SCHEMBL11811596 0.60 SIGMAR1 (0.50) AMPD2SIGMAR1CYP2C9CYP2C19CYP1A2
SCHEMBL3483026 0.60 HTR3E (0.59) SIGMAR1CYP3A4GRIN2BHTR3EHTR3B
SCHEMBL10423175 0.58 SLC6A4 (0.46) SIGMAR1CYP3A4SLC6A4SLC6A3SLC6A2
SCHEMBL9667972 0.58 SLC6A4 (0.50) SIGMAR1CYP3A4SLC6A4SLC6A3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed
WO-2016075137-A1 SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 ACAT2 1935/4885AMPD2 3495/4885SIGMAR1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback